The Role of Lazertinib in Patients With <i>EGFR</i>-Variant Non–Small Cell Lung Cancer

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2024-08-15
DOI
https://doi.org/10.1001/jamaoncol.2024.2607
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Role of Lazertinib in Patients With EGFR-Variant Non–Small Cell Lung Cancer

Haiying Cheng
JAMA Oncology
Lung Cancer Treatments and Mutations
article

The Role of Lazertinib in Patients With EGFR-Variant Non–Small Cell Lung Cancer

Haiying Cheng
article en

Abstract

No abstract available for this paper.
JAMA OncologyVol. 10(10)
Albert Einstein College of Medicine (US), Montefiore Medical Center (US)
Good health and well-being
Openalex Percentile: Top 76%
Lung Cancer Treatments and Mutations
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The Role of Lazertinib in Patients With <i>EGFR</i>-Variant Non–Small Cell Lung Cancer — Haiying Cheng · JAMA Oncology (2024) | TGRS Research Map | TGRS